Current Affairs - Science - Discussion

Menkes disease is a rare genetic disorder caused by a mutation that disrupts copper transport in the body, leading to severe developmental and physiological issues in affected children. Zycubo (copper histidinate) is the first FDA-approved treatment for this condition. Administered by injection, it bypasses the defective copper absorption mechanism and significantly improves survival, especially when started within four weeks of birth. Clinical trials showed that early-treated children had a 78% lower risk of death. Monitoring is important due to possible copper toxicity, emphasizing careful management during treatment.